How to Take Kerendia (Finerenone)

Take Kerendia once daily by mouth, with the starting dose determined by your kidney function (eGFR): 20 mg daily if eGFR ≥60 mL/min/1.73m², or 10 mg daily if eGFR is 25-59 mL/min/1.73m²—and you must have your potassium level checked before starting (must be ≤5.0 mEq/L to begin treatment). 1

Before Starting Kerendia

Your doctor must check two critical values before prescribing:

Serum potassium: Must be ≤5.0 mEq/L (do not start if higher) 1
eGFR: Determines your starting dose; initiation not recommended if <25 mL/min/1.73m² 1

Starting Dose Based on Kidney Function

For CKD with Type 2 Diabetes:

eGFR ≥60: Start 20 mg once daily 1
eGFR 25-59: Start 10 mg once daily 1
eGFR <25: Do not initiate 1

For Heart Failure (LVEF ≥40%):

Same starting doses, but target doses differ (20 mg if eGFR 25-59 at initiation; 40 mg if eGFR ≥60 at initiation) 1

How to Take the Medication

Swallow tablets whole once daily 1
Can be taken with or without food 1, 2
If unable to swallow: Crush and mix immediately with water or soft foods like applesauce 1
Missed dose: Take as soon as remembered on the same day; if you remember the next day, skip it and resume normal schedule 1

Critical Monitoring Schedule

Potassium monitoring is essential to prevent dangerous hyperkalemia:

4 weeks after starting: Check potassium and adjust dose 1
4 weeks after any dose change: Recheck potassium 1
Every 4 months during stable treatment: Ongoing monitoring 3

This frequent monitoring is necessary because finerenone blocks mineralocorticoid receptors, which can cause potassium retention 3.

Dose Adjustments Based on Potassium (CKD with Type 2 Diabetes)

If currently on 10 mg daily:

Potassium ≤4.8 mEq/L: Increase to 20 mg daily (unless eGFR dropped >30%) 1
Potassium 4.9-5.5 mEq/L: Continue 10 mg daily 1
Potassium >5.5 mEq/L: Stop medication; restart at 10 mg when potassium ≤5.0 mEq/L 1

If currently on 20 mg daily:

Potassium ≤4.8 mEq/L: Continue 20 mg daily 1
Potassium 4.9-5.5 mEq/L: Continue 20 mg daily 1
Potassium >5.5 mEq/L: Stop medication; restart at 10 mg when potassium ≤5.0 mEq/L 1

The KDIGO 2024 guidelines align with these FDA recommendations, emphasizing that only patients with consistently normal potassium should receive finerenone 3.

Important Drug Interactions

Avoid or adjust with CYP3A4 inhibitors (finerenone is metabolized primarily by this enzyme):

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): Contraindicated—do not use together 2
Moderate/weak CYP3A4 inhibitors (erythromycin, verapamil, grapefruit juice): Monitor potassium more frequently and adjust dose as needed 2
Strong/moderate CYP3A4 inducers (rifampin, phenytoin, St. John's wort): Avoid—they reduce finerenone effectiveness 2

Common Pitfalls to Avoid

Starting with high potassium: Never initiate if potassium >5.0 mEq/L—this is the most critical safety issue 1
Inadequate monitoring: Missing the 4-week potassium check can lead to dangerous hyperkalemia 3
Ignoring eGFR decline: If eGFR drops >30% from baseline, maintain current dose rather than increasing 1
Combining with strong CYP3A4 inhibitors: This is contraindicated and can cause severe hyperkalemia 2

Clinical Context

Finerenone is recommended by KDIGO 2024 guidelines as a nonsteroidal MRA for patients with type 2 diabetes, eGFR >25 mL/min/1.73m², and albuminuria >30 mg/g despite maximum tolerated RAS inhibitor therapy 3. It can be added to SGLT2 inhibitors and RAS inhibitors for comprehensive cardiorenal protection 3. The medication reduces risk of kidney disease progression, cardiovascular death, heart failure hospitalization, and myocardial infarction 1, 4.

How should I take Kerendia (finerenone)?

Have a follow-up question?